Skip to main content
. 2020 Mar 30;34(3):255–263. doi: 10.1007/s40259-020-00411-4

Fig. 2.

Fig. 2

European survey results highlighting the under-dosing of filgrastim by both weight and duration of therapy. The survey of 88 healthcare professionals (78 physicians; 10 pharmacists) from six European countries (Germany n = 3; Italy n = 7; Portugal n = 31; Poland n = 29; Lithuania n = 12; Latvia n = 6) was undertaken in April–May 2019. Respondents were based in oncology clinics (n = 3); general hospitals (n = 36); or specialist haematology or oncology centres (n = 48). HCPs healthcare professionals